Fig. 4

Treatment recommendations for case 3, a clinically low-risk LGG with a high-risk molecular pattern, in 12/2016 (left panel) and 2015 (right panel). Patients with clinically low-risk constellations but a high-risk molecular pattern were also more likely to receive active treatment after RTOG 9802 (34% in 2015 vs. 50% in 2016). Currently, a temozolomide-based radiochemotherapy is the preferred regimen within the centers (27% in 2016 vs. 10% in 2015)